These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 36123113)
1. Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain. Pike CK; Kim M; Schnitzer K; Mercaldo N; Edwards R; Napadow V; Zhang Y; Morrissey EJ; Alshelh Z; Evins AE; Loggia ML; Gilman JM BMJ Open; 2022 Sep; 12(9):e063613. PubMed ID: 36123113 [TBL] [Abstract][Full Text] [Related]
2. Assessing the potential anti-neuroinflammatory effect of minocycline in chronic low back pain: Protocol for a randomized, double-blind, placebo-controlled trial. Morrissey EJ; Alshelh Z; Knight PC; Saha A; Kim M; Torrado-Carvajal A; Zhang Y; Edwards RR; Pike C; Locascio JJ; Napadow V; Loggia ML Contemp Clin Trials; 2023 Mar; 126():107087. PubMed ID: 36657520 [TBL] [Abstract][Full Text] [Related]
3. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial. Efron D; Taylor K; Payne JM; Freeman JL; Cranswick N; Mulraney M; Prakash C; Lee KJ; Williams K BMJ Open; 2020 Mar; 10(3):e034362. PubMed ID: 32152170 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. Hendricks O; Andersen TE; Christiansen AA; Primdahl J; Hauge EM; Ellingsen T; Horsted TI; Bachmann AG; Loft AG; Bojesen AB; Østergaard M; Lund Hetland M; Krogh NS; Roessler KK; Petersen KH BMJ Open; 2019 Jun; 9(6):e028197. PubMed ID: 31167870 [TBL] [Abstract][Full Text] [Related]
5. Neuroimmune signatures in chronic low back pain subtypes. Alshelh Z; Brusaferri L; Saha A; Morrissey E; Knight P; Kim M; Zhang Y; Hooker JM; Albrecht D; Torrado-Carvajal A; Placzek MS; Akeju O; Price J; Edwards RR; Lee J; Sclocco R; Catana C; Napadow V; Loggia ML Brain; 2022 Apr; 145(3):1098-1110. PubMed ID: 34528069 [TBL] [Abstract][Full Text] [Related]
6. Effects of pulsed low-frequency magnetic field therapy on pain intensity in patients with musculoskeletal chronic low back pain: study protocol for a randomised double-blind placebo-controlled trial. Abdulla FA; Alsaadi S; Sadat-Ali M; Alkhamis F; Alkawaja H; Lo S BMJ Open; 2019 Jun; 9(6):e024650. PubMed ID: 31182440 [TBL] [Abstract][Full Text] [Related]
7. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol. Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233 [TBL] [Abstract][Full Text] [Related]
8. Protocol for a pragmatic trial of Cannabidiol (CBD) to improve chronic pain symptoms among United States Veterans. Bergmans RS; Wegryn-Jones R; Klida C; Kurtz V; Thomas L; Williams DA; Clauw DJ; Kidwell KM; Bohnert ASB; Boehnke KF BMC Complement Med Ther; 2024 Jun; 24(1):250. PubMed ID: 38951902 [TBL] [Abstract][Full Text] [Related]
9. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial. Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P Trials; 2024 May; 25(1):293. PubMed ID: 38693590 [TBL] [Abstract][Full Text] [Related]
10. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). Mersiades AJ; Tognela A; Haber PS; Stockler M; Lintzeris N; Simes J; McGregor I; Olver I; Allsop DJ; Gedye C; Kirby AC; Morton RL; Fox P; Clarke S; Briscoe K; Aghmesheh M; Wong N; Walsh A; Hahn C; Grimison P BMJ Open; 2018 Sep; 8(9):e020745. PubMed ID: 30209152 [TBL] [Abstract][Full Text] [Related]
11. Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial. Bawa Z; McCartney D; Bedoya-Pérez M; Lau NS; Fox R; MacDougall H; McGregor IS BMJ Open; 2024 Mar; 14(3):e082927. PubMed ID: 38531572 [TBL] [Abstract][Full Text] [Related]
12. Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults. Koychev I; Adler AI; Edison P; Tom B; Milton JE; Butchart J; Hampshire A; Marshall C; Coulthard E; Zetterberg H; Hellyer P; Cormack F; Underwood BR; Mummery CJ; Holman RR BMJ Open; 2024 Jun; 14(6):e081401. PubMed ID: 38908839 [TBL] [Abstract][Full Text] [Related]
13. Optimising treatment expectations in chronic lower back pain through observing others: a study protocol for a randomised clinical trial. Stuhlreyer J; Schwartz M; Friedheim T; Zöllner C; Klinger R BMJ Open; 2022 Jan; 12(1):e059044. PubMed ID: 35017258 [TBL] [Abstract][Full Text] [Related]
14. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447 [TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
16. The C4EB study-Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study. Schräder NHB; Duipmans JC; Renken RJ; Sörös P; Vermeulen KM; Bolling MC; Wolff AP PLoS One; 2022; 17(12):e0277512. PubMed ID: 36508401 [TBL] [Abstract][Full Text] [Related]
17. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy. Perry MS Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420 [TBL] [Abstract][Full Text] [Related]
18. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. van der Flier FE; Kwee CMB; Cath DC; Batelaan NM; Groenink L; Duits P; van der Veen DC; van Balkom AJLM; Baas JMP BMC Psychiatry; 2019 Feb; 19(1):69. PubMed ID: 30760241 [TBL] [Abstract][Full Text] [Related]
19. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Bebee B; Taylor DM; Bourke E; Pollack K; Foster L; Ching M; Wong A Med J Aust; 2021 May; 214(8):370-375. PubMed ID: 33846971 [TBL] [Abstract][Full Text] [Related]
20. Evidence for brain glial activation in chronic pain patients. Loggia ML; Chonde DB; Akeju O; Arabasz G; Catana C; Edwards RR; Hill E; Hsu S; Izquierdo-Garcia D; Ji RR; Riley M; Wasan AD; Zürcher NR; Albrecht DS; Vangel MG; Rosen BR; Napadow V; Hooker JM Brain; 2015 Mar; 138(Pt 3):604-15. PubMed ID: 25582579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]